Work

15P Clinical relevance of tumor fraction assessment from circulating tumor DNA and RNF43 mutations as predictors of anti-BRAF/EGFR outcomes in metastatic colorectal cancer

Year: 2025

Type: article

Study design: Observational Study

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2025.05.027

Authors: R.D.A. Toledo, V. Morris, R.P. Graf, S. Kopetz, J.C.F. Quintanilha

Institutions: Vall d'Hebron Institute of Oncology, The University of Texas MD Anderson Cancer Center, Foundation Medicine (United States)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Merck KGaA, Incyte, Foundation Medicine

Award: G490769284

OpenAlex ID: W4412480189

FWCI: 0.353

Cites: 2

Cited by: 1

Related to: 10